text: A 2014 Cochrane review found insufficient evidence to make a conclusion about its use for the prevention of heart disease. A 2016 Cochrane review concluded that CoQ had no effect on blood pressure. A 2021 Cochrane review found "no convincing evidence to support or refute" the use of CoQ for the treatment of heart failure.
  A 2017 meta-analysis of people with heart failure 30–100 mg/d of CoQ found a 31% lower mortality and increased exercise capacity, with no significant difference in the endpoints of left heart ejection fraction.
  In a 2023 meta-analysis of older people ubiquinone was compared with ubiquinol. The results demonstrate a beneficial cardiovascular effect of ubiquinone. This could not be confirmed for ubiquinol.